Every 8-K that Pfizer Inc. (PFE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PFE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFE filings page.
Pfizer Inc. reported second-quarter 2026 revenues of $15.0 billion, up 3% year over year (1% operational). Excluding Comirnaty and Paxlovid, revenues grew 5% operationally and launched and acquired products delivered 18% operational revenue growth. The quarter showed a reported loss per share of $(0.04), driven by $4.3 billion in non-cash intangible asset impairments, while Adjusted diluted EPS was $0.77, roughly in line with the prior year.
Pfizer raised its full-year 2026 revenue guidance midpoint by $500 million to a range of $60.5–$62.5 billion, reflecting stronger non-COVID performance and lower COVID-19 product expectations of about $4 billion. Full-year 2026 Adjusted diluted EPS guidance of $2.80–$3.00 was reaffirmed and incorporates a $650 million acquired in-process R&D charge for the Innovent Biologics collaboration.
Capital deployment in the first half of 2026 included $5.3 billion invested in internal R&D, about $170 million in business development, and $4.9 billion in dividends ($0.86 per share). Pfizer also expanded its productivity programs, targeting an additional $2.5 billion of anticipated cost savings from 2027 through 2029, and reported multiple positive late-stage and regulatory milestones across oncology, vaccines, hematology, and obesity.
Pfizer Inc. is announcing a planned Chief Financial Officer transition. Dave Denton will step down as CFO and leave Pfizer on August 15, 2026 to take a role in the consumer goods industry. The company states his departure is not related to Pfizer’s financial or operating results or any disagreements over financial, operational, accounting or reporting policies.
Pfizer has appointed Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer effective August 16, 2026, while it conducts a comprehensive internal and external search for a permanent successor. Guegan, 55, has more than two decades at Pfizer and recently led finance for the global biopharmaceutical business and played a key role in integrating Seagen into Pfizer in 2024.
Pfizer Inc. reported first-quarter 2026 results and reaffirmed its full‑year 2026 financial guidance. Revenues were $14.5 billion, up 5% year over year (2% operational), with 7% operational growth excluding Comirnaty and Paxlovid, and 22% operational growth from launched and acquired products.
Reported diluted EPS was $0.47 versus $0.52 a year ago, while adjusted diluted EPS was $0.75 versus $0.92, reflecting higher cost of sales, increased R&D and acquired IPR&D expenses. Pfizer maintained 2026 revenue guidance of $59.5–$62.5 billion and adjusted diluted EPS guidance of $2.80–$3.00, invested $2.5 billion in internal R&D and returned $2.4 billion in dividends. Recent developments include strong growth in products such as Padcev, Eliquis and oncology biosimilars, positive Phase 2/3 readouts across several pipeline programs, a $1.875 billion exit from its ViiV Healthcare stake, and Vyndamax patent settlements extending effective U.S. patent expiry to June 1, 2031.
Pfizer Inc. reported results of its Annual Meeting of Shareholders held on April 23, 2026. All director nominees were elected with support generally above three billion votes each, and KPMG LLP was ratified as independent registered public accounting firm with 4,160,827,231 votes in favor.
Shareholders approved the Pfizer Inc. 2019 Stock Plan, as amended April 2026, with 3,227,692,578 votes for, and approved on an advisory basis the 2026 compensation of the Named Executive Officers with 3,099,249,442 votes for. A shareholder proposal to adopt an independent chair policy did not pass, receiving 1,015,206,372 votes for and 2,509,042,021 votes against.
Pfizer Inc. filed a current report to make investors aware that it has released its financial results for the fourth quarter of 2025. The company did this by issuing a press release on February 3, 2026, which is attached to the report as Exhibit 99.
The press release is formally provided for information purposes and is not treated as being legally “filed” under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Pfizer Inc. furnished a regulatory disclosure stating that it issued a press release providing its full-year 2026 financial guidance and revising its full-year 2025 revenue guidance.
The company reaffirmed all other components of its full-year 2025 financial guidance in the same press release, which is attached as an exhibit to the disclosure.
Pfizer Inc. completed a multi-tranche public notes offering, issuing $500,000,000 of Floating Rate Notes due 2027 and several series of fixed-rate notes with maturities from 2027 to 2065. The fixed-rate tranches include $1,000,000,000 of 3.875% Notes due 2027, $1,000,000,000 of 4.200% Notes due 2030, $1,250,000,000 of 4.500% Notes due 2032, $1,250,000,000 of 4.875% Notes due 2035, $500,000,000 of 5.600% Notes due 2055 and $500,000,000 of 5.700% Notes due 2065. The notes were issued under Pfizer’s existing shelf registration statement and an indenture with The Bank of New York Mellon, with Citigroup, Deutsche Bank, J.P. Morgan and Mizuho acting as lead underwriters.
Pfizer Inc. completed its acquisition of Metsera, Inc. The deal converted each Metsera share into $65.60 in cash at closing, representing an enterprise value of approximately $7.0 billion, plus a non-transferable contingent value right (CVR) worth up to $20.65 per share upon achieving specified milestones.
The CVR includes three potential cash payments tied to Metsera’s GLP‑1 programs:
- $4.60 per share upon initiation of the Phase 3 clinical trial of the MET-097i (GLP-1 receptor antagonist) + MET-233i (amylin analog) combination.
- $6.40 per share upon FDA approval of monthly MET-097i monotherapy.
- $9.65 per share upon FDA approval of monthly MET-097i + MET-233i combination.
Pfizer Inc. filed an 8-K announcing its third-quarter 2025 financial results. The company furnished a press release as Exhibit 99 dated November 4, 2025, detailing the quarter’s performance. The information under Item 2.02 (Results of Operations and Financial Condition) is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings except by specific reference. An Inline XBRL cover page file is also included as Exhibit 104.